Recombinant Human CD30 Ligand/TNFSF8 Protein, CF | R&D Systems 1028-CL product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Human CD30 Ligand/TNFSF8 Protein, CF

catalog :

1028-CL

quantity :

50 ug

price :

239 USD

citations: 6

Reference
Clarke A, Poulton L, Shim D, Mabon D, Butt D, Pollard M, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10:664-677 pubmed publisher
Wilson T, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487:505-9 pubmed publisher
Simhadri V, Hansen H, Simhadri V, Reiners K, Bessler M, Engert A, et al. A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells. Biol Chem. 2012;393:101-6 pubmed publisher
Suzuki O, Hirsch B, Abe M, Dürkop H, Stein H. Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells. Lab Invest. 2012;92:191-9 pubmed publisher
Lobito A, Ramani S, Tom I, Bazan J, Luis E, Fairbrother W, et al. Murine insulin growth factor-like (IGFL) and human IGFL1 proteins are induced in inflammatory skin conditions and bind to a novel tumor necrosis factor receptor family member, IGFLR1. J Biol Chem. 2011;286:18969-81 pubmed publisher
Schwertassek U, Balmer Y, Gutscher M, Weingarten L, Preuss M, Engelhard J, et al. Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1. EMBO J. 2007;26:3086-97 pubmed

product information

brand :

R&D Systems

master code :

1028-CL

SKU :

1028-CL-050

product name :

Recombinant Human CD30 Ligand/TNFSF8 Protein, CF

description :

The Recombinant Human CD30 Ligand/TNFSF8 Protein, CF from R&D Systems is derived from NS0. The Recombinant Human CD30 Ligand/TNFSF8 Protein, CF has been validated for the following applications: Bioactivity.

target :

CD30 Ligand/TNFSF8

category :

Proteins and Enzymes

unit size :

50 ug

buffer :

Lyophilized from a 0.2 µm filtered solution in PBS.

conjugate :

Unconjugated

purity :

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

species :

Human

observed molecular weight :

30-40 kDa, reducing conditions

theoretical molecular weight :

22 kDa

gene symbol :

TNFSF8

details of functionality :

Measured by its ability to stimulate IL-6 secretion by HDLM human Hodgkin’s lymphoma cells. Duckett, C.S. et al . (1997) Mol. Cell. Biol. 17 :1535. The ED50 for this effect is 8-48 ng/mL in the presence of 10 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # MAB050 ).

endotoxin note :

<0.10 EU per 1 µg of the protein by the LAL method.

catalog number base :

1028-CL

accessionNumbers :

P32971

applications :

Bioactivity

source :

Mouse myeloma cell line, NS0-derived human CD30 Ligand/TNFSF8 protein MHHHHHHHHHH GGGSGGGSGGGS IEGR Human CD30 Ligand (Gln63-Asp234) Accession # P32971 N-terminus C-terminus

2020 USD :

239

2021 USD :

239 USD

alt names :

CD153, CD153 antigen, CD30 antigen ligand, CD30L, CD30-L, CD30LCD30 ligand, CD30LGMGC138144, TNFSF8, tumor necrosis factor (ligand) superfamily, member 8, tumor necrosis factor ligand superfamily member 8

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.